Trending...
- Bethany Nikitenko Appointed to Philadelphia Trial Lawyers Association Board of Directors
- LiteracyNation's 3rd Annual Indie Author Book Fair
- Why Baton Rouge's Humid Climate Can Contribute to Carpenter Ant Damage — J&J Exterminating Explains How to Protect Your Home
PHILADELPHIA, Dec. 4, 2024 ~ Franklin Biolabs, a newly established contract research organization (CRO) focused on genetic medicines, has announced the appointment of Vatsala Naageshwaran, PhD, as its Chief Executive Officer. The company was founded by renowned gene therapy pioneer, James Wilson, MD, PhD.
Dr. Naageshwaran brings over 20 years of experience in the biopharmaceutical industry to her new role at Franklin Biolabs. She is a highly accomplished executive with a strong commitment to advancing advanced therapies for patients. Throughout her career, she has successfully led cross-functional teams and delivered significant revenues to support business growth.
"We are thrilled to have Vatsala join our team at Franklin Biolabs," said Dr. Wilson, Chairperson of the company. "Her exceptional combination of business acumen and technical scientific expertise will be invaluable as we continue to grow and bring transformative therapies to patients with rare and debilitating diseases."
More on The PennZone
Prior to joining Franklin Biolabs, Dr. Naageshwaran held various leadership positions at biotech companies such as Myriad Genetics and Astex Pharmaceuticals. She also served as the Chief Business Officer at Absorption Systems, a contract research organization based in Exton, PA. In this role, she was responsible for driving the global business strategy for integrated services supporting small molecules, medical devices, and cell and gene therapies.
Most recently, Dr. Naageshwaran was the Vice President and Head of Business Development for US CGT & Lab Services at Pharmaron – a global service provider supporting large pharmaceutical and biotech companies in developing cell and gene therapy products.
"I am honored to join Franklin Biolabs and be a part of their groundbreaking work in gene therapy and healthcare innovation," said Dr. Naageshwaran. "I am confident that my experience will contribute to the development of innovative therapeutics that will have a profound impact on patients' lives worldwide."
More on The PennZone
Dr. Naageshwaran holds degrees in biochemistry and molecular biology from Mount Holyoke College and pharmacometrics from the University of Maryland, Baltimore. She also completed her doctoral work in pharmaceutical drug research through a joint program between the University of Helsinki and Eastern Finland.
Her expertise has been recognized by the FDA, as she has received IDIQ and BAA grants to study PK/PD of complex products. Under her leadership, Pharmaron's San Diego site was named a Top CRO from 2018-2021. In 2021, she was nominated for the San Diego Business Woman of the Year Award. Dr. Naageshwaran's research has been presented at national conferences such as Association for Research in Vision and Ophthalmology (ARVO), American Association of Pharmaceutical Scientists (AAPS), Science of Toxicology (SOT), and American Association for Cancer Research (AACR). She has also authored multiple publications submitted to peer-reviewed journals.
With Dr. Naageshwaran at the helm, Franklin Biolabs is poised to make significant strides in advancing genetic medicines and improving patient outcomes. Her leadership and expertise will undoubtedly play a crucial role in the company's success as it continues to bring innovative therapies to those in need.
Dr. Naageshwaran brings over 20 years of experience in the biopharmaceutical industry to her new role at Franklin Biolabs. She is a highly accomplished executive with a strong commitment to advancing advanced therapies for patients. Throughout her career, she has successfully led cross-functional teams and delivered significant revenues to support business growth.
"We are thrilled to have Vatsala join our team at Franklin Biolabs," said Dr. Wilson, Chairperson of the company. "Her exceptional combination of business acumen and technical scientific expertise will be invaluable as we continue to grow and bring transformative therapies to patients with rare and debilitating diseases."
More on The PennZone
- New Book Calls 'Sense of Belonging' the Missing Link in Student Success
- Igbozue Connecticut USA Celebrates 2026 Summer Family Picnic
- KT Medical Staffing Addresses the Questions Families Forget to Ask Before Bringing Private Nursing Care Home
- Private Autopsies Give Arizona Families Answers After Nursing Home and Care Facility Deaths
- Chuckie F. Mahoney Memorial Foundation Awards Nearly $40,000 in School Grants
Prior to joining Franklin Biolabs, Dr. Naageshwaran held various leadership positions at biotech companies such as Myriad Genetics and Astex Pharmaceuticals. She also served as the Chief Business Officer at Absorption Systems, a contract research organization based in Exton, PA. In this role, she was responsible for driving the global business strategy for integrated services supporting small molecules, medical devices, and cell and gene therapies.
Most recently, Dr. Naageshwaran was the Vice President and Head of Business Development for US CGT & Lab Services at Pharmaron – a global service provider supporting large pharmaceutical and biotech companies in developing cell and gene therapy products.
"I am honored to join Franklin Biolabs and be a part of their groundbreaking work in gene therapy and healthcare innovation," said Dr. Naageshwaran. "I am confident that my experience will contribute to the development of innovative therapeutics that will have a profound impact on patients' lives worldwide."
More on The PennZone
- OPUS Global Data Solutions Launches Food Trader Plus, Bringing Operational Control and Deal-Level Profit Visibility to Food Brokers
- Phinge CEO DeMaio Unveils Speech to Congress: User Data Sovereignty vs Tech Surveillance Capitalism, Asserting Foundational 2021 App-Less Patents & IP
- Michael Maertens Hired as Century Fasteners Corp. – Chief Financial Officer
- LATO AI Software Innovations Expedite Inspections & Repair of Parking Lots for The Pavement Group
- Built to Last: Why BSI Is Among the Nation's Fastest-Growing Companies, and One of Its Best Places to Work
Dr. Naageshwaran holds degrees in biochemistry and molecular biology from Mount Holyoke College and pharmacometrics from the University of Maryland, Baltimore. She also completed her doctoral work in pharmaceutical drug research through a joint program between the University of Helsinki and Eastern Finland.
Her expertise has been recognized by the FDA, as she has received IDIQ and BAA grants to study PK/PD of complex products. Under her leadership, Pharmaron's San Diego site was named a Top CRO from 2018-2021. In 2021, she was nominated for the San Diego Business Woman of the Year Award. Dr. Naageshwaran's research has been presented at national conferences such as Association for Research in Vision and Ophthalmology (ARVO), American Association of Pharmaceutical Scientists (AAPS), Science of Toxicology (SOT), and American Association for Cancer Research (AACR). She has also authored multiple publications submitted to peer-reviewed journals.
With Dr. Naageshwaran at the helm, Franklin Biolabs is poised to make significant strides in advancing genetic medicines and improving patient outcomes. Her leadership and expertise will undoubtedly play a crucial role in the company's success as it continues to bring innovative therapies to those in need.
0 Comments
Latest on The PennZone
- UK Financial Ltd Makes History: Chainlink CRE Circulating Supply Verification Goes Live Across Its Complete Ecosystem Of Nine Exchange-Traded Tokens
- International Rights Groups Raise Alarm Over Freedom of Religion and Expression in South Korea
- The City's Most Elegant Open-Air Dinner Party Returns September 12, 2026
- LiteracyNation's 3rd Annual Indie Author Book Fair
- FDA Clears Major Regulatory Hurdle as Preservative-Free Ketamine Program Moves Within Reach of Commercialization: NRx Pharmaceuticals: (NAS DAQ: NRXP)
- Autonomous Robotics Platform Expansion as Public Market Debut is Very Close: MBody AI Corp. (N A S D A Q: MBAI)
- Loud! OOH calls for prize draw advertising standards as £1.3bn category moves outdoors
- Insurance for Braces Helps Make Treatment More Manageable for Pennsylvania Families
- Black Ribbon Productions Launches With Fearless 2026 Horror Slate
- Actor Dominic Pace Returns to Television and Film
- Opteamix welcomes Girish Ramachandra to its leadership team as Senior Vice President of Client Services
- Silicon Box Ships 500M Units at High Yield, Expands Production Capacity for Panel-Level Packaging
- Bethany Nikitenko Appointed to Philadelphia Trial Lawyers Association Board of Directors
- Why Baton Rouge's Humid Climate Can Contribute to Carpenter Ant Damage — J&J Exterminating Explains How to Protect Your Home
- Meals on Wheels of the Greater Lehigh Valley Awarded $50,000 Grant from Harry C. Trexler Trust
- RPR Promotes Emily Line to Chief Strategy Officer and Janine Sieja to Chief Product Officer
- Kellyn Hosts Fourth Lehigh Valley Lifestyle Medicine Symposium
- Expanding Beyond Space as New Drone Market Opportunities Accelerate Growth: Ascent Solar Technologies (N A S D A Q: ASTI)
- Lauren Merrell, Dale Sorensen Real Estate, announces price improvement for an extraordinary island retreat
- Portalz Publishes FES World First Architecture Introducing a New Cryptographic Platform